IVVD Invivyd, Inc.Stock Price & Overview
$2.22
Charts
Quant Ranking
IVVD Analysis
IVVD News
Latest Headlines
Ratings Summary
People Also Follow
Similar to IVVD
ETFs Holding IVVD
IVVD Company Profile
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
IVVD Revenue
IVVD Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
IVVD Ownership
IVVD Peers
Risk
Technicals
IVVD Transcripts
Investor Presentations
IVVD SEC Filings
Press Releases
IVVD Income Statement
IVVD Balance Sheet
IVVD Cash Flow Statement
IVVD Long Term Solvency
Discover More
You may be interested in: